Sionna Therapeutics today announced the official launch of the company and the closing of a $111 million Series B financing. The round was led by OrbiMed with participation from funds advised by T.
Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the ...
Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- ...
Please provide your email address to receive an email when new articles are posted on . Challenged urine bicarbonate excretion provided a simple and safe quantification of cystic fibrosis ...
The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights. Scientists at St. Jude Children's Research Hospital and ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers have succeeded in developing a so-called nanobody that penetrates directly ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ...
Scientists at St. Jude Children's Research Hospital and Rockefeller University have combined their expertise to gain a better understanding of the cystic fibrosis transmembrane conductance regulator ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
(Memphis, Tenn.—March 22, 2023) Scientists at St. Jude Children’s Research Hospital and Rockefeller University have combined their expertise to gain a better understanding of the cystic fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results